Livingston Group Asset Management CO operating as Southport Capital Management Has $1.20 Million Stake in Thermo Fisher Scientific Inc. (TMO)

Livingston Group Asset Management CO operating as Southport Capital Management decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 4,382 shares of the medical research company’s stock after selling 121 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Thermo Fisher Scientific were worth $1,199,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. CX Institutional purchased a new position in Thermo Fisher Scientific during the first quarter valued at $36,000. Freestone Capital Holdings LLC raised its position in shares of Thermo Fisher Scientific by 46.1% in the 4th quarter. Freestone Capital Holdings LLC now owns 10,081 shares of the medical research company’s stock worth $2,256,000 after purchasing an additional 3,180 shares during the last quarter. Putnam FL Investment Management Co. raised its position in shares of Thermo Fisher Scientific by 2.9% in the 4th quarter. Putnam FL Investment Management Co. now owns 29,001 shares of the medical research company’s stock worth $6,490,000 after purchasing an additional 810 shares during the last quarter. Steinberg Global Asset Management raised its position in shares of Thermo Fisher Scientific by 21.1% in the 1st quarter. Steinberg Global Asset Management now owns 5,747 shares of the medical research company’s stock worth $1,187,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Calamos Advisors LLC raised its position in shares of Thermo Fisher Scientific by 5.4% in the 4th quarter. Calamos Advisors LLC now owns 132,462 shares of the medical research company’s stock worth $29,644,000 after purchasing an additional 6,769 shares during the last quarter. 88.84% of the stock is owned by institutional investors.

TMO has been the subject of several research analyst reports. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Bank of America reiterated a “buy” rating and issued a $300.00 price objective (up from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Argus lifted their price objective on Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Deutsche Bank lifted their price objective on Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. Finally, Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $270.00 to $288.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus target price of $294.77.

Shares of Thermo Fisher Scientific stock traded up $0.18 during trading hours on Friday, reaching $269.18. 1,548,512 shares of the stock traded hands, compared to its average volume of 1,892,196. The company has a market cap of $107.59 billion, a P/E ratio of 24.21, a P/E/G ratio of 1.76 and a beta of 1.11. Thermo Fisher Scientific Inc. has a one year low of $202.83 and a one year high of $282.98. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.07. The business had revenue of $6.13 billion during the quarter, compared to the consensus estimate of $6.04 billion. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.50 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.19 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 16th. Investors of record on Friday, March 15th were paid a dividend of $0.19 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 6.83%.

In related news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $266.00, for a total transaction of $665,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Peter E. Hornstra sold 5,920 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $250.00, for a total value of $1,480,000.00. Following the transaction, the chief accounting officer now owns 17,057 shares of the company’s stock, valued at $4,264,250. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 87,640 shares of company stock valued at $23,243,423. 0.45% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Livingston Group Asset Management CO operating as Southport Capital Management Has $1.20 Million Stake in Thermo Fisher Scientific Inc. (TMO)” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/11/livingston-group-asset-management-co-operating-as-southport-capital-management-has-1-20-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.